Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus docetaxel/cisplatin induction chemotherapy followed by concurrent chemoradiotherapy in T4/N3 non-metastatic nasopharyngeal carcinoma
ChiCTR2500114985Phase 2Recruiting
- Sponsor
- Shanghai Proton and Heavy Ion Center
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in nasopharyngeal carcinoma (NPC), sponsored by Shanghai Proton and Heavy Ion Center. Primary endpoint: Objective Response Rate. Started Dec 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2500114985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114985.